Mesoblast Limited (MESO) News
Follow Mesoblast Limited (MESO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Mesoblast reports Q1 net revenues up 44%
EARNINGS | Oct 29, 2026, 01:17 AM UTC
L
MESO - Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
MESO - Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
REGULATION | Sep 24, 2026, 11:00 AM UTC
M
Mesoblast reports revenue growth to US$120M
Mesoblast reported substantial revenue growth to US$120M.
EQUITY | Aug 27, 2026, 12:32 AM UTC
L
MESO - Mesoblast Financial Results and Corporate Update Webcast
MESO - Mesoblast Financial Results and Corporate Update Webcast
EQUITY | Aug 24, 2026, 11:00 AM UTC
L
Mesoblast completes dosing in Phase 3 back pain trial
Mesoblast Limited says it has concluded patient dosing for its Phase 3 MSB-DR004 trial of rexlemestrocel-L in chronic low back pain linked to inflammatory degenerative disc disease.
EARNINGS | Aug 17, 2026, 05:45 PM UTC
H
Mesoblast (MESO) completes patient treatment in pivotal Phase 3
Mesoblast (MESO) says it has achieved a major milestone by completing patient treatment in its pivotal Phase 3 trial for chronic low back pain.
EQUITY | Aug 17, 2026, 12:35 AM UTC
H
Mesoblast: Ryoncil Net Revenues $36M
Mesoblast reports Ryoncil revenues
EQUITY | Jul 30, 2026, 12:57 AM UTC
H
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Wednesday. Shares of PayPal Holdings Inc (NASDAQ: PYPL ) rose sharply following a report that Stripe and Advent International have proposed a
RATES | Jul 15, 2026, 01:56 PM UTC
H
Earnings Flash (MESO) Mesoblast Limited Reports Q4 Revenue $36.0M, vs. FactSet Est of $36.9M
() -- Copyright © 2026. All rights reserved. does not provide investment advice. Unauthorized reproduction is strictly prohibited.
EARNINGS | Jul 10, 2026, 08:23 AM UTC
L
Reported Earlier, Mesoblast Secures BLA Filing Number For Rexlemestrocel-L, Backed By Orphan Drug And RMAT Designations For Priority Review
Reported Earlier, Mesoblast Secures BLA Filing Number For Rexlemestrocel-L, Backed By Orphan Drug And RMAT Designations For Priority Review Eligibility
EQUITY | Jul 01, 2026, 07:34 AM UTC